Matthew W Jenner

List of Publications by Citations

73 papers	1,923 citations	21 h-index	43 g-index
73 ext. papers	2,307 ext. citations	4.6 avg, IF	4.01 L-index

#	Paper	IF	Citations
73	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. *Blood*, **2010**, 116, e56-65	2.2	263
72	Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. *Blood*, **2006**, 108, 1733-43	2.2	163
71	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 57-73	21.7	154
70	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. *Blood*, **2007**, 110, 3291-300	2.2	121
69	Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. *Clinical Cancer Research*, **2010**, 16, 1856-64	12.9	109
68	Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. *Leukemia*, **2018**, 32, 102-110	10.7	108
67	MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. *Haematologica*, **2009**, 94, 78-86	6.6	94
66	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. *British Journal of Haematology*, **2007**, 137, 268-9	4.5	86
65	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). *Leukemia*, **2017**, 31, 107-114	10.7	81
64	Deletions of CDKN2C in multiple myeloma: biological and clinical implications. *Clinical Cancer Research*, **2008**, 14, 6033-41	12.9	77
63	The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. *Haematologica*, **2007**, 92, 1149-50	6.6	62
62	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. *British Journal of Haematology*, **2010**, 150, 326-33	4.5	56
61	Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. *Blood Cancer Journal*, **2016**, 6, e506	7	49
60	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. *British Journal of Haematology*, **2013**, 162, 107-11	4.5	45
59	The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. *Leukemia and Lymphoma*, **2006**, 47, 2335-8	1.9	38
58	Advances in oral therapy for multiple myeloma. *Lancet Oncology, The*, **2006**, 7, 316-25	21.7	34
57	The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. *Leukemia*, **2020**, 34, 604-612	10.7	32

56	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). *Leukemia*, **2020**, 34, 1840-1852	10.7	30
55	Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study.. *Blood*, **2007**, 110, 3593-3593	2.2	29
54	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e616-e629	14.6	26
53	Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. *Blood*, **2020**, 136, 1091-1104	2.2	23
52	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. *Cancer Immunology, Immunotherapy*, **2015**, 64, 1021-32	7.4	21
51	Subclonal copy number is associated with prognosis in multiple myeloma. *Blood*, **2018**, 132, 2465-2469	2.2	21
50	Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. *British Journal of Haematology*, **2017**, 176, 908-917	4.5	19
49	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood*, **2021**, 137, 1154-1165	2.2	18
48	Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 7777-7782	11.5	17
47	Updates to the guidelines for the diagnosis and management of multiple myeloma. *British Journal of Haematology*, **2014**, 167, 131-3	4.5	14
46	Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. *European Journal of Haematology*, **2008**, 81, 432-6	3.8	14
45	Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. *Leukemia*, **2020**, 34, 3091-3096	10.7	13
44	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. *Journal of Clinical Oncology*, **2019**, 37, 1617-1628	2.2	12
43	Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 551-555	4.5	11
42	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. *Leukemia*, **2021**, 35, 2043-2053	10.7	10
41	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). *Blood*, **2018**, 132, 1994-1994	2.2	7
40	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. *Haematologica*, **2021**, 106, 1957-1967	6.6	6
39	The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).. *Blood*, **2006**, 108, 3537-3537	2.2	5

38	MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. *BMJ Open*, **2021**, 11, e046225	3	5
37	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. *British Journal of Haematology*, **2021**, 192, 853-868	4.5	5
36	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.. *Journal of Clinical Oncology*, **2022**, JCO2102228	2.2	5
35	Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial. *Blood*, **2018**, 132, 3278-3278	2.2	4
34	CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma. *Blood*, **2008**, 112, 3707-3707	2.2	4
33	Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients. *Blood*, **2015**, 126, 189-189	2.2	4
32	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. *Haematologica*, **2020**, Online ahead of print,	6.6	4
31	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 154-161.e3	2	4
30	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. *PLoS Medicine*, **2021**, 18, e1003454	11.6	4
29	Liposomal cytarabine in cerebrospinal fluid. *British Journal of Haematology*, **2009**, 145, 679	4.5	3
28	A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. *Blood*, **2019**, 134, 1890-1890	2.2	3
27	Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.. *Blood*, **2006**, 108, 3555-3555	2.2	2
26	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). *Blood*, **2016**, 128, 4412-4412	2.2	2
25	Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance. *Blood*, **2019**, 134, 3132-3132	2.2	1
24	Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.. *Blood*, **2006**, 108, 112-112	2.2	1
23	Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.. *Blood*, **2007**, 110, 395-395	2.2	1
22	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 667-675	2	1
21	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. *European Journal of Haematology*, **2022**, 108, 73-83	3.8	1

20	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. *Advances in Therapy*, **2021**, 38, 1328-1341	4.1	1
19	The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients.. *Blood*, **2007**, 110, 2727-2727	2.2	0
18	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. *BMJ Open*, **2022**, 12, e056147	3	0
17	Insights into the Basis of Chromosomal Imbalances during the Clonal Evolution of Multiple Myeloma Using SNP Array Analysis.. *Blood*, **2005**, 106, 621-621	2.2	
16	Identification of Collaborating Oncogeneic Events Leading to Disease Progression in Myeloma Cases with a t(4;14) and t(11;14) Using SNP and Gene Expression Arrays.. *Blood*, **2005**, 106, 1542-1542	2.2	
15	Status of Chromosome 13 in Multiple Myeloma: Integrated Approach Using SNP Mapping Array and Gene Expression Array.. *Blood*, **2005**, 106, 1563-1563	2.2	
14	Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD.. *Blood*, **2006**, 108, 110-110	2.2	
13	Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.. *Blood*, **2006**, 108, 3390-3390	2.2	
12	Thalidomide in Combination with Idarubicin, Dexamethasone and Etoposide (TIDE) Is an Effective Oral Combination in Heavily Pre-Treated Myeloma Patients.. *Blood*, **2007**, 110, 4841-4841	2.2	
11	Genome-Wide Identification of Gene Expression Networks Affected by Genomic Changes in Multiple Myeloma.. *Blood*, **2007**, 110, 2494-2494	2.2	
10	Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.. *Blood*, **2007**, 110, 2473-2473	2.2	
9	Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.. *Blood*, **2007**, 110, 2474-2474	2.2	
8	An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.. *Blood*, **2007**, 110, 2493-2493	2.2	
7	Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant. *Blood*, **2019**, 134, 3120-3120	2.2	
6	Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial. *Blood*, **2015**, 126, 1852-1852	2.2	
5	The Impact of Constitutional Copy Number Variants in Myeloma. *Blood*, **2008**, 112, 496-496	2.2	
4	Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.. *Blood*, **2008**, 112, 1694-1694	2.2	
3	High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma. *Blood*, **2008**, 112, 625-625	2.2	

2	XBP1 Expression Is An Important Prognostic Factor for Newly Diagnosed Myeloma Patients.. *Blood*, **2008**, 112, 1686-1686	2.2
1	Homozygous Deletions Can Be Used to Define a Cell Death Specific Gene Expression Signature Able to Predict Outcome in Myeloma. *Blood*, **2008**, 112, 2725-2725	2.2